The U.S. Food and Drug Administration (FDA) recently approved the addition of two molybdenum-99 (Mo-99) filling lines at NorthStar’s facility in Columbia, Mo., which will immediately increase Mo-99 production efficiencies. These new filling lines are part of NorthStar’s ongoing expansion plans to increase production and capacity of domestic, non-uranium based Mo-99 for the U.S. healthcare system.
Empty Source Vessel Staging Area
Hot Cell and Shielded Storage Area
Filled Source Vessel Inspection Glove Box
Expansion activities in Columbia run in parallel with NorthStar’s ongoing expansions in Beloit, Wis., where NorthStar’s Isotope Processing facility is nearing completion, and will augment processing at the University of Missouri Research Reactor (MURR®).
The Isotope Processing facility will house multiple dissolution hot cells, decay-in-storage vaults, a state-of-the-art Radiation Laboratory, multiple Fill Lines housed in an ISO Class 8 Clean Room, automated packaging & shipping lines to support dissolution, filling, & shipment of Mo-99 Source Vessels and a cMo-98 and aMo-100 Reclamation Suite.
NorthStar plans to have dual Mo-99 processing and production hubs in Wisconsin and Missouri. In addition, construction of the Accelerator Production facility is underway, with the initial pair of electron beam accelerators being assembled in Belgium. We believe that all these efforts will further secure reliable, non-uranium based Mo-99 radioisotope supply for the U.S. healthcare system.